# Lajos Pusztai

Source: https://onco.cc/people/lajos-pusztai/  
OnCo record `lajos-pusztai` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Translational breast oncologist who co-leads the I-SPY2 platform trial and helped show immunotherapy works in early TNBC.

## Summary

Lajos Pusztai (Yale Cancer Center) co-leads the I-SPY2 adaptive neoadjuvant platform, whose durvalumab and pembrolizumab arms provided the first randomised evidence that checkpoint inhibitors raise pathological complete response in triple-negative breast cancer, before KEYNOTE-522 confirmed it. He led the SWOG S1418 adjuvant pembrolizumab trial and has published widely on immune gene signatures. His current focus is response-adapted de-escalation.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: tnbc; platform-trial; biomarkers
- Role: Professor of Medicine and Co-Leader, Genetics, Genomics and Epigenetics Program, Yale Cancer Center
- Specialisms: Triple-negative breast cancer; Adaptive platform trials; Immune biomarkers; Neoadjuvant therapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Pusztai%20L%5BAuthor%5D%20triple-negative%20I-SPY

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [Yale Cancer Center / Smilow Cancer Hospital](https://onco.cc/institutions/yale-cancer-center/)
- journals: [Cancer Cell](https://onco.cc/journals/cancer-cell/)
- roadmaps: [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/lajos-pusztai.json